comparemela.com

Latest Breaking News On - Punit dhillon - Page 6 : comparemela.com

Skye Bioscience Begins Dosing Phase 1 Fourth Cohort in Clinical Trial of Novel CB1R Agonist

Skye Bioscience Begins Dosing Phase 1 Fourth Cohort in Clinical Trial of Novel CB1R Agonist
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South australiaSan diegoUnited statesSkye biosciencePunit dhillonExchange commissionUs drug enforcement agencySkye bioscience incCalifornia newsfile corpChief executive officerInvestigational new drugEnforcement agencyRisk factors

Skye Bioscience s Novel Cannabinoid Derivative Reduces Pain in Animal Model; Results Published in Scientific Journal

San Diego, California (Newsfile Corp. - April 3, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ( Skye or the Company ), a pharmaceutical company .

San diegoUnited statesSkye biosciencePunit dhillonUniversity of mississippiCalifornia newsfile corpCannabinoid researchSkye bioscience incChief executive officerNovel cannabidiol analogOxycodone place preferenceOpioid abuse deterrentAnalgesic properties

Skye Bioscience, Inc : Skye Bioscience Receives Human Research Ethics Committee Approval to Start Multiple Ascending Dose Arm of Phase 1 Study of SBI-100 Ophthalmic Emulsion

San Diego, California (Newsfile Corp. - March 15, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative

San diegoUnited statesUnited kingdomDennis riedlSkye biosciencePunit dhillonExchange commissionSkye bioscience incCalifornia newsfile corpGlaucoma research foundationChief executive officerBritish journalRisk factors

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

Skye bioscienceNatalie stobermanPunit dhillon

Skye Bioscience moving ahead with SBI-100 clinical trial after positive safety review

Skye Bioscience CEO Punit Dhillon joins Natalie Stoberman from the Proactive newsroom to discuss the positive safety review for its Phase 2 clinical trial.

Skye bioscienceNatalie stobermanPunit dhillon

vimarsana © 2020. All Rights Reserved.